A growing reliance on industry-sponsored cancer clinical trials in the United States is a reason for concern, say researchers from the UNC Lineberger Comprehensive Cancer Center.

Expanding Capabilities to Support Early and Late-Stage Drug Development with Comprehensive Manufacturing SolutionsElkridge, Maryland--(Newsfile ...

VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis ...

Eva Madrid, the Lead of Cochrane’s new Iberoamérica Evidence Synthesis Unit, spoke on the panel of the launch event for the ...

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 ...

Over the past decade, decreasing vaccination rates now threaten the huge beneficial impacts of vaccinations in the U.S. and globally. Researchers discuss the multifactorial barriers including ...

Dr. Barry Davies joins Mosaic Therapeutics as CSO, bringing 25 years of drug discovery expertise to advance targeted oncology therapies and precision medicine.

Significant investments in digital health, telemedicine, and Artificial Intelligence (AI)-driven diagnostics have reshaped ...